IL94961A - Suspensions of surfactants with low viscosity and high concentration and their production - Google Patents

Suspensions of surfactants with low viscosity and high concentration and their production

Info

Publication number: IL94961A
Authority: IL; Israel
Prior art keywords: surfactant; calcium; mmol; magnesium; suspending agent
Prior art date: 1989-07-04

Application number

IL9496190A

Other languages

English (en)

Hebrew (he)

Other versions

IL94961A0 (en

Original Assignee

Thomae Gmbh Dr K

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-04

Filing date

1990-07-03

Publication date

1994-10-21

1990-07-03 Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K

1991-06-10 Publication of IL94961A0 publication Critical patent/IL94961A0/xx

1994-10-21 Publication of IL94961A publication Critical patent/IL94961A/en

Links

239000004094 surface-active agent Substances 0.000 title claims abstract description 123
239000000725 suspension Substances 0.000 title claims abstract description 76
238000004519 manufacturing process Methods 0.000 title claims description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 62
239000011575 calcium Substances 0.000 claims abstract description 61
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 60
229910001424 calcium ion Inorganic materials 0.000 claims abstract description 53
239000000375 suspending agent Substances 0.000 claims abstract description 35
229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 32
239000011780 sodium chloride Substances 0.000 claims abstract description 28
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 21
238000009256 replacement therapy Methods 0.000 claims abstract description 15
208000018569 Respiratory Tract disease Diseases 0.000 claims abstract description 3
229910052791 calcium Inorganic materials 0.000 claims description 41
238000000034 method Methods 0.000 claims description 33
235000002639 sodium chloride Nutrition 0.000 claims description 28
239000000463 material Substances 0.000 claims description 25
150000003904 phospholipids Chemical class 0.000 claims description 22
150000002632 lipids Chemical class 0.000 claims description 21
239000011777 magnesium Substances 0.000 claims description 21
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 19
229910052749 magnesium Inorganic materials 0.000 claims description 19
210000004072 lung Anatomy 0.000 claims description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
239000007788 liquid Substances 0.000 claims description 12
102000004169 proteins and genes Human genes 0.000 claims description 12
108090000623 proteins and genes Proteins 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
239000008346 aqueous phase Substances 0.000 claims description 9
239000012074 organic phase Substances 0.000 claims description 9
239000003580 lung surfactant Substances 0.000 claims description 8
238000009826 distribution Methods 0.000 claims description 7
238000000746 purification Methods 0.000 claims description 6
210000002345 respiratory system Anatomy 0.000 claims description 6
238000000432 density-gradient centrifugation Methods 0.000 claims description 5
230000002209 hydrophobic effect Effects 0.000 claims description 4
230000007935 neutral effect Effects 0.000 claims description 4
238000005406 washing Methods 0.000 claims description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
159000000003 magnesium salts Chemical class 0.000 claims description 3
238000007865 diluting Methods 0.000 claims description 2
238000004108 freeze drying Methods 0.000 claims description 2
241000257303 Hymenoptera Species 0.000 claims 1
230000001476 alcoholic effect Effects 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
229960005069 calcium Drugs 0.000 description 39
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 33
239000001110 calcium chloride Substances 0.000 description 18
229910001628 calcium chloride Inorganic materials 0.000 description 18
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 17
235000011148 calcium chloride Nutrition 0.000 description 17
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
241000283690 Bos taurus Species 0.000 description 8
229940091250 magnesium supplement Drugs 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 7
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 7
238000003860 storage Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 6
206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
201000002652 newborn respiratory distress syndrome Diseases 0.000 description 6
239000000203 mixture Substances 0.000 description 5
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
-1 Mg2+ ions Chemical class 0.000 description 4
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
238000002604 ultrasonography Methods 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010036590 Premature baby Diseases 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
206010001053 acute respiratory failure Diseases 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000005057 refrigeration Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
201000004193 respiratory failure Diseases 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
SYDXVIKBJDOFKI-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;magnesium Chemical compound [Mg].OC(=O)[C@@H](N)CCC(O)=O SYDXVIKBJDOFKI-DFWYDOINSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
206010003598 Atelectasis Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000011692 calcium ascorbate Substances 0.000 description 1
235000010376 calcium ascorbate Nutrition 0.000 description 1
229940047036 calcium ascorbate Drugs 0.000 description 1
239000004227 calcium gluconate Substances 0.000 description 1
235000013927 calcium gluconate Nutrition 0.000 description 1
229960004494 calcium gluconate Drugs 0.000 description 1
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
239000001527 calcium lactate Substances 0.000 description 1
235000011086 calcium lactate Nutrition 0.000 description 1
229960002401 calcium lactate Drugs 0.000 description 1
PWKNEBQRTUXXLT-ZBHRUSISSA-L calcium lactate gluconate Chemical compound [Ca+2].CC(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O PWKNEBQRTUXXLT-ZBHRUSISSA-L 0.000 description 1
MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 1
235000010244 calcium sorbate Nutrition 0.000 description 1
239000004303 calcium sorbate Substances 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
208000030499 combat disease Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
DIXGJWCZQHXZNR-UHFFFAOYSA-L magnesium citrate Chemical compound [Mg+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O DIXGJWCZQHXZNR-UHFFFAOYSA-L 0.000 description 1
229960005336 magnesium citrate Drugs 0.000 description 1
235000002538 magnesium citrate Nutrition 0.000 description 1
239000004337 magnesium citrate Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229940025511 phospholipid / protein Drugs 0.000 description 1
238000005375 photometry Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pulmonology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Toxicology (AREA)
Physiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Virology (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Colloid Chemistry (AREA)
Artificial Filaments (AREA)

IL9496190A 1989-07-04 1990-07-03 Suspensions of surfactants with low viscosity and high concentration and their production IL94961A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3921954A DE3921954A1 (de)	1989-07-04	1989-07-04	Niedrig-viskose, hochkonzentrierte surfactant-suspension

Publications (2)

Publication Number	Publication Date
IL94961A0 IL94961A0 (en)	1991-06-10
IL94961A true IL94961A (en)	1994-10-21

Family

ID=6384269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9496190A IL94961A (en)	1989-07-04	1990-07-03	Suspensions of surfactants with low viscosity and high concentration and their production

Country Status (24)

Country	Link
US (1)	US5552161A (fr)
EP (1)	EP0406732B1 (fr)
JP (1)	JP3103582B2 (fr)
KR (1)	KR0162642B1 (fr)
AT (1)	ATE122891T1 (fr)
AU (1)	AU623538B2 (fr)
CA (1)	CA2020209C (fr)
DD (1)	DD297916A5 (fr)
DE (2)	DE3921954A1 (fr)
DK (1)	DK0406732T3 (fr)
ES (1)	ES2072940T3 (fr)
FI (1)	FI95655C (fr)
HK (1)	HK1000277A1 (fr)
HU (1)	HU205004B (fr)
IE (1)	IE68448B1 (fr)
IL (1)	IL94961A (fr)
NO (1)	NO180620C (fr)
NZ (2)	NZ234341A (fr)
PH (1)	PH30232A (fr)
PL (1)	PL164434B1 (fr)
PT (1)	PT94574B (fr)
RU (1)	RU2077880C1 (fr)
UA (1)	UA26313A (fr)
ZA (1)	ZA905182B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4418936A1 (de) *	1994-05-31	1996-02-08	Byk Gulden Lomberg Chem Fab	Polypeptid
US6129934A (en) *	1995-06-07	2000-10-10	Ony, Inc.	Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
US6172203B1 (en) *	1996-02-07	2001-01-09	Alfredo Adolfo Hager	Method for extracting and purifying pulmonary surfactant
AU6083899A (en)	1999-09-16	2001-04-17	Aventis Behring Gmbh	Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
EP1249244A1 (fr)	2001-04-13	2002-10-16	Universiteit Gent	Compositions thérapeutiques pour le traitement d'une maladie influencée par l'équilibre G-actin / F-actin, p.e. une maladie respiratoire
DE50214446D1 (de)	2001-10-11	2010-07-01	Nycomed Gmbh	Neue verwendung von lungensurfactant
US8337815B2 (en) *	2004-12-23	2012-12-25	Discovery Laboratories, Inc.	Pulmonary surfactant formulations
JP4734328B2 (ja) *	2005-05-11	2011-07-27	ヤマサ醤油株式会社	肺サーファクタント蛋白質の安定化法
US8048043B2 (en) *	2007-06-08	2011-11-01	Chiesi Farmaceutici S. P. A.	Method of administration of a pulmonary surfactant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55160721A (en) *	1979-06-02	1980-12-13	Tokyo Tanabe Co Ltd	Pulmonary surfactant ta-546, its preparation, and remedy for pulmonary hyaline membrane syndrome comprising it as active constituent
EP0110498B2 (fr) *	1982-11-22	1991-09-18	Teijin Limited	Surfactant pulmonaire artificiel et remède le contenant comme principe actif pour le syndrome d'insuffisance respiratoire
JPS59164724A (ja) *	1983-03-10	1984-09-17	Tokyo Tanabe Co Ltd	サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
CS938384A1 (en) *	1983-12-08	1990-08-14	Lachmann Burkhardt	Pharmaceutical agent for breathlesness therapy and method of its production
IT1203873B (it) *	1987-04-08	1989-02-23	Chiesi Farma Spa	Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e

1989
- 1989-07-04 DE DE3921954A patent/DE3921954A1/de not_active Withdrawn
1990
- 1990-06-29 CA CA002020209A patent/CA2020209C/fr not_active Expired - Fee Related
- 1990-06-30 ES ES90112513T patent/ES2072940T3/es not_active Expired - Lifetime
- 1990-06-30 DE DE59009113T patent/DE59009113D1/de not_active Expired - Lifetime
- 1990-06-30 DK DK90112513.8T patent/DK0406732T3/da active
- 1990-06-30 EP EP90112513A patent/EP0406732B1/fr not_active Expired - Lifetime
- 1990-06-30 AT AT90112513T patent/ATE122891T1/de not_active IP Right Cessation
- 1990-07-02 DD DD90342432A patent/DD297916A5/de not_active IP Right Cessation
- 1990-07-02 PL PL90285904A patent/PL164434B1/pl not_active IP Right Cessation
- 1990-07-03 NZ NZ234341A patent/NZ234341A/en unknown
- 1990-07-03 IL IL9496190A patent/IL94961A/en not_active IP Right Cessation
- 1990-07-03 ZA ZA905182A patent/ZA905182B/xx unknown
- 1990-07-03 IE IE240890A patent/IE68448B1/en not_active IP Right Cessation
- 1990-07-03 NZ NZ242869A patent/NZ242869A/en unknown
- 1990-07-03 PT PT94574A patent/PT94574B/pt not_active IP Right Cessation
- 1990-07-03 PH PH40776A patent/PH30232A/en unknown
- 1990-07-03 NO NO902961A patent/NO180620C/no unknown
- 1990-07-03 UA UA5010226A patent/UA26313A/uk unknown
- 1990-07-03 JP JP02176092A patent/JP3103582B2/ja not_active Expired - Fee Related
- 1990-07-03 FI FI903341A patent/FI95655C/fi active IP Right Grant
- 1990-07-03 HU HU904077A patent/HU205004B/hu not_active IP Right Cessation
- 1990-07-04 KR KR1019900010052A patent/KR0162642B1/ko not_active Expired - Fee Related
- 1990-07-04 AU AU58676/90A patent/AU623538B2/en not_active Ceased
1991
- 1991-12-09 RU SU915010226A patent/RU2077880C1/ru not_active IP Right Cessation
1995
- 1995-05-01 US US08/432,386 patent/US5552161A/en not_active Expired - Lifetime
1997
- 1997-09-26 HK HK97101844A patent/HK1000277A1/xx unknown

Also Published As

Publication number	Publication date
DE59009113D1 (de)	1995-06-29
IL94961A0 (en)	1991-06-10
IE68448B1 (en)	1996-06-26
IE902408A1 (en)	1991-06-19
FI903341A0 (fi)	1990-07-03
NO902961D0 (no)	1990-07-03
EP0406732B1 (fr)	1995-05-24
PH30232A (en)	1997-02-05
JPH0344332A (ja)	1991-02-26
JP3103582B2 (ja)	2000-10-30
FI95655B (fi)	1995-11-30
EP0406732A3 (en)	1991-02-27
US5552161A (en)	1996-09-03
DE3921954A1 (de)	1991-01-17
RU2077880C1 (ru)	1997-04-27
NZ242869A (en)	1997-05-26
KR0162642B1 (ko)	1998-12-01
DK0406732T3 (da)	1995-10-02
ATE122891T1 (de)	1995-06-15
ZA905182B (en)	1992-03-25
ES2072940T3 (es)	1995-08-01
KR910002427A (ko)	1991-02-25
NO902961L (no)	1991-01-07
EP0406732A2 (fr)	1991-01-09
PL164434B1 (pl)	1994-07-29
HU904077D0 (en)	1990-12-28
AU5867690A (en)	1991-01-10
AU623538B2 (en)	1992-05-14
PT94574B (pt)	1997-02-28
CA2020209A1 (fr)	1991-01-05
HUT56274A (en)	1991-08-28
DD297916A5 (de)	1992-01-30
PT94574A (pt)	1991-03-20
CA2020209C (fr)	2000-09-12
HK1000277A1 (en)	1998-02-20
NZ234341A (en)	1992-07-28
HU205004B (en)	1992-03-30
UA26313A (uk)	1999-08-30
NO180620B (no)	1997-02-10
NO180620C (no)	1997-05-21
FI95655C (fi)	1996-03-11

Legal Events

Date	Code	Title
1996-10-16	KB	Patent renewed
2000-10-31	KB	Patent renewed
2009-08-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0119056B1 (fr)	1990-08-29	Composition tensio-actif et compositions pharmaceutiques le renfermant et son utilisation pour le traitement du syndrome d'oppression respiratoire
US4348384A (en)	1982-09-07	Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
DE68929248T2 (de)	2001-01-25	Oberflächenaktives lungenprotein und verwandte polypeptide
HU211950A9 (en)	1996-01-29	Natural pulmonary surfactant, method of preparation and pharmaceutical compositions
GB2050832A (en)	1981-01-14	Surface active material containing phospholipid lipid carbohydrate and protein
HU210323B (en)	1995-03-28	Process for producing growth hormone crystals
US5552161A (en)	1996-09-03	Low viscosity, highly concentrated surfactant suspension
KR20030053507A (ko)	2003-06-28	동적-팽창 작용을 하는 폐계면활성제 조성물
WO1995015980A1 (fr)	1995-06-15	Nouveau peptide synthetique, tensioactif pulmonaire contenant ledit peptide et remede contre le syndrome de souffrance respiratoire
US4738952A (en)	1988-04-19	Substitute for human blood and a method of making the same
EP0145005B1 (fr)	1989-04-12	Tensio-actif pulmonaire, procédé de préparation et utilisation pharmaceutique
DE69928279T2 (de)	2006-08-17	Lungensurfactant zubereitungen enthaltendes behandlungset
HK1000277B (en)	1998-02-20	Highly concentrated and low-viscosity surfactant suspension
US4853370A (en)	1989-08-01	Substitute for human blood and a method of making the same
JP3376582B2 (ja)	2003-02-10	合成ペプチド、それを含有する肺サーファクタント及び呼吸窮迫症候群治療剤
WO1985005035A1 (fr)	1985-11-21	Substance de remplacement du sang humain et son procede de production
JPH0129171B2 (fr)	1989-06-08
KR19980016013A (ko)	1998-05-25	적혈구 용혈 억제용 약제학적 조성물 및 그의 제조방법
Davies	1956	Effect of fat on the vitamin K requirement of the chick.
JPS6361000A (ja)	1988-03-17	リポ蛋白質及びその製造法